$2.180
-0.096 (-4.39%)Al cierre
Comparativa sectorial de RNAZ
In the context of the broader market, RNAZ competes directly with industry leaders such as QNTM and ELUT. With a market capitalization of $9.90M, it holds a significant position in the sector. When comparing efficiency, RNAZ's gross margin of N/A stands against QNTM's N/A and ELUT's 57.87%. Such benchmarking helps identify whether Transcode Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Transcode Therapeutics Inc
Transcode Therapeutics has shown consistently negative net income over the past quarters, with Q2 2026 net income at -6,865,143. The company has a current ratio of 1.97, indicating it can cover its short-term liabilities, but the overall financial outlook remains bleak with a total equity of -27,694,917 in Q2 2026.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.